LivaNova (LIVN) to Release Quarterly Earnings on Tuesday

LivaNova (NASDAQ:LIVN) is expected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect LivaNova to post earnings of $0.80 per share and revenue of $324.11 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

LivaNova Trading Down 1.1 %

Shares of NASDAQ:LIVN opened at $47.44 on Friday. The firm has a fifty day moving average of $47.95 and a two-hundred day moving average of $49.54. The firm has a market capitalization of $2.58 billion, a P/E ratio of 112.95 and a beta of 1.00. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LIVN shares. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday, January 28th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $69.17.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.27% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.